As Congress prepares to begin its new term, newly elected lawmakers will convene to tackle issues such as the high cost of drugs. As they prepare to address these policy challenges, a new analysis shows that several key congressional leaders have received major contributions from the pharmaceutical industry.
As Congress prepares to begin its new term, newly elected lawmakers will convene to tackle issues such as the high cost of drugs. As they prepare to address these policy challenges, a new analysis shows that several key congressional leaders have received major contributions from the pharmaceutical industry.
Kaiser Health News (KHN) has reported that several legislators who will wield much of the power in the House in 2019 are among the representatives and senators who have received the most money from the pharmaceutical industry.
Steny Hoyer, D-Maryland; James Clyburn, D-South Carolina; Kevin McCarthy, R-California; and Richard Burr, R-North Carolina, have each received more than $1 million in donations from pharmaceutical companies’ political action committees (PACs) in the past 10 years. Hoyer and Clyburn were recently selected by Democrats to serve as the incoming majority leader and majority whip, respectively. Burr serves on the Senate Committee on Health, Education, Labor, and Pensions.
Over the past decade, says KHN, members of Congress from both parties have accepted approximately $81 million from 68 individual pharma PACs.
Additionally, tax disclosure forms show that the Pharmaceutical Research and Manufacturers of America (PhRMA), a trade group that represents the interests of drug makers including Amgen and Johnson & Johnson, raised revenue by approximately one-fourth in 2016, and spent the collected monies among hundreds of lobbyists, politicians, and patient groups that could further its interests.
The group has attempted to cultivate a bipartisan reputation, but PhRMA may be incented to shift its 2019 lobbying efforts to the Republican-controlled Senate from the Democrat-controlled house. STAT has reported a conversation with a drug industry lobbyist who called the House of Representatives a “dead zone” for industry interests in light of the results of the midterm election and renewed concerns about the high cost of drugs.
Meanwhile, PhRMA has initiated a campaign—called Let’s Talk About Cost—aimed directly at consumers. The campaign addresses such questions as why other countries have lower drug prices, why copay coupons may not count toward deductibles, and who decides what customers pay for their prescription drugs.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.